



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/82162/2025
EMA/H/C/006794

Usrenty (*ustekinumab*)

An overview of Usrenty and why it is authorised in the EU

What is Usrenty and what is it used for?

Usrenty is a medicine used to treat:

- moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin). It is used in adults and children from the age of 6 years whose condition has not improved with, or who cannot use, other systemic (whole-body) psoriasis treatments, such as ciclosporin, methotrexate or PUVA (psoralen ultraviolet A). PUVA is a type of treatment where the patient receives a medicine called psoralen, before being exposed to ultraviolet light;
- active psoriatic arthritis (inflammation of the joints associated with psoriasis) in adults, when the condition has not improved enough with other treatments called disease-modifying anti-rheumatic drugs (DMARDs). Usrenty may be used alone or combined with methotrexate (a DMARD);
- moderately to severely active Crohn's disease (a disease-causing inflammation of the gut) in adults whose condition has not improved enough with other treatments for Crohn's disease or who cannot receive such treatments.

Usrenty contains the active substance ustekinumab and is a biological medicine. It is a 'biosimilar medicine'; this means that Usrenty is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Usrenty is Stelara. For more information on biosimilar medicines, see [here](#).

How is Usrenty used?

Usrenty can only be obtained with a prescription and should be given under the supervision of a doctor who has experience in diagnosing and treating the diseases that Usrenty is used for.

In plaque psoriasis and psoriatic arthritis, Usrenty is injected under the skin. The first injection is followed by another injection 4 weeks later. After that, one injection is given every 12 weeks.

In Crohn's disease, Usrenty treatment is started as an infusion (drip) into a vein lasting at least 1 hour. Eight weeks after the first infusion, Usrenty is given as an injection under the skin. Patients then continue with Usrenty given as an injection under the skin every 8 or 12 weeks, depending on how well the treatment is working.

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Patients or their caregivers may inject Usrenty once they have been trained, if their doctor thinks that this is appropriate.

For more information about using Usrenty, see the package leaflet or contact your doctor or pharmacist.

How does Usrenty work?

The active substance in Usrenty, ustekinumab, is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific target in the body. Ustekinumab attaches to 2 messenger molecules in the immune system called interleukin 12 and interleukin 23. Both are involved in inflammation and other processes that are important in psoriasis, psoriatic arthritis and Crohn's disease. By blocking their activity, ustekinumab reduces the activity of the immune system and the symptoms of these diseases.

What benefits of Usrenty have been shown in studies?

Laboratory studies comparing Usrenty with the reference medicine Stelara have shown that the active substance in Usrenty is highly similar to that in Stelara in terms of structure, purity and biological activity. Studies have also shown that giving Usrenty produces similar levels of the active substance in the body to those seen with Stelara.

In addition, a study involving 384 adults with moderate to severe plaque psoriasis showed that Usrenty was as effective as Stelara at improving symptoms of the disease. After 12 weeks of treatment, PASI scores (a measure of disease severity and area of skin affected) had improved by around 80% in people receiving Usrenty and around 81% in those receiving Stelara.

Because Usrenty is a biosimilar medicine, the studies on the effectiveness of ustekinumab carried out with Stelara do not all need to be repeated for Usrenty.

What are the risks associated with Usrenty?

For the full list of side effects and restrictions with Usrenty, see the package leaflet.

The safety of Usrenty has been evaluated and, on the basis of all the studies carried out, the side effects of the medicine are considered to be comparable to those of the reference medicine Stelara.

The most common side effects with ustekinumab (which may affect more than 1 in 20 people) include headache and nasopharyngitis (inflammation of the nose and throat). The most serious side effect with ustekinumab (which may affect up to 1 in 1,000 people) is serious hypersensitivity (allergic) reactions including anaphylaxis (sudden, severe allergic reaction with breathing difficulty, swelling, lightheadedness, fast heartbeat, sweating and loss of consciousness).

Usrenty must not be used in patients who have an active infection that the doctor considers important.

Why is Usrenty authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Usrenty has a highly similar structure, purity and biological activity to Stelara and is distributed in the body in the same way. In addition, a study in adults with plaque psoriasis has shown that Usrenty and Stelara are equivalent in terms of safety and effectiveness in this condition.

All these data were considered sufficient to conclude that Usrenty will have the same effects as Stelara in its authorised uses. Therefore, the Agency's view was that, as for Stelara, the benefits of Usrenty outweigh the identified risks and it can be authorised for use in the EU.

What measures are being taken to ensure the safe and effective use of Usrenty?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Usrenty have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Usrenty are continuously monitored. Suspected side effects reported with Usrenty are carefully evaluated and any necessary action taken to protect patients.

Other information about Usrenty

Usrenty received a marketing authorisation valid throughout the EU on 17 September 2025.

Further information on Usrenty can be found on the Agency's website:

ema.europa.eu/medicines/human/EPAR/usrenty.

This overview was last updated in 08-2025.